← ACET
ACET— Adicet Bio, Inc.
MaterialsPharmaceutical Preparations
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue related party | $0-100.0% | $25.0M |
| Research and development | $106.0M+48.8% | $71.2M |
| General and administrative | $26.5M+0.9% | $26.3M |
| Goodwill impairment | $19.5M | $0 |
| Total operating expenses | $152.0M+55.9% | $97.5M |
| Loss from operations | -$152.0M-109.6% | -$72.6M |
| Interest income | $10.0M+165.4% | $3.8M |
| Interest expense | -$25K+68.8% | -$80K |
| Other expense, net | -$573K+37.6% | -$919K |
| Loss before income tax provision | -$142.7M-104.4% | -$69.8M |
| Income tax provision | $0 | $0 |
| Net loss | -$142.7M-104.4% | -$69.8M |
| Net loss per share attributable to common stockholders, basic | -$3K-94.7% | -$2K |
| Net loss per share attributable to common stockholders, diluted | -$3K-94.7% | -$2K |
| Weighted-average common shares used in computing net income (loss) per share attributable to common stockholders, basic | $43.04B+4.8% | $41.08B |
| Weighted-average common shares used in computing net income (loss) per share attributable to common stockholders, diluted | $43.04B+4.8% | $41.08B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.